3XB0 Stock Overview
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Xenetic Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.76 |
| 52 Week High | US$4.28 |
| 52 Week Low | US$3.41 |
| Beta | 2.58 |
| 1 Month Change | -11.32% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 5.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3XB0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.1% | -3.2% | 2.0% |
| 1Y | n/a | -25.4% | 5.9% |
Return vs Industry: Insufficient data to determine how 3XB0 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 3XB0 performed against the German Market.
Price Volatility
| 3XB0 volatility | |
|---|---|
| 3XB0 Average Weekly Movement | 5.1% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3XB0 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 3XB0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 4 | Jeff Eisenberg | www.xeneticbio.com |
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company’s proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors.
Xenetic Biosciences, Inc. Fundamentals Summary
| 3XB0 fundamental statistics | |
|---|---|
| Market cap | €5.57m |
| Earnings (TTM) | -€4.15m |
| Revenue (TTM) | €2.27m |
2.5x
P/S Ratio-1.3x
P/E RatioIs 3XB0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3XB0 income statement (TTM) | |
|---|---|
| Revenue | US$2.44m |
| Cost of Revenue | US$0 |
| Gross Profit | US$2.44m |
| Other Expenses | US$6.92m |
| Earnings | -US$4.47m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.90 |
| Gross Margin | 100.00% |
| Net Profit Margin | -182.95% |
| Debt/Equity Ratio | 0% |
How did 3XB0 perform over the long term?
See historical performance and comparison